2-cyclopropyl-3-(2'-carboxybiphenyl-4-yl)methyl-7-methyl-3H-imidazo[4,5-b]pyridine | 135070-05-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-cyclopropyl-3-(2'-carboxybiphenyl-4-yl)methyl-7-methyl-3H-imidazo[4,5-b]pyridine
• 英文别名: E4177；4'-(2-cyclopropyl-7-methyl-3H-imidazo[5,4-b]pyridine-3-yl)methyl-2-biphenylcarboxylic acid；3-[(2'-carboxybiphenyl-4-yl)methyl]-2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridine；3-((2'-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine；2-[4-[(2-cyclopropyl-7-methylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]benzoic acid
• CAS: 135070-05-2
• 化学式: C₂₄H₂₁N₃O₂
• 分子量: 383.45
• InChiKey: VWWMGPCUZVOLLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-Cyclopropyl-3-{(2'-methoxycarbonylbiphenyl-4-yl)methyl}-7-methyl-3H-imidazo[4,5-b]pyridine 生成 2-cyclopropyl-3-(2'-carboxybiphenyl-4-yl)methyl-7-methyl-3H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  Biphenylmethane derivative and pharmacological use

  摘要：

  化合物(I)是一种联苯甲烷衍生物，可用于预防和治疗高血压和心力衰竭。 ##STR1## 其中R1是氢，烷基，环烷基，卤代烷基，--S--R7，--SO2--R7，--C.tbd.C--R7或--(CH2)p--OR7，R7是氢，烷基，环烷基或卤代烷基，p为零或1，--A1.dbd.A2--A3.dbd.A4--是--CH.dbd.CH--CH.dbd.CH--，--N.dbd.CH--CH.dbd.CH--，--CH.dbd.N--CH.dbd.CH--，--CH.dbd.CH--N.dbd.CH--，--CH.dbd.CH--CH.dbd.N--或--CH.dbd.N--CH.dbd.N--，R2和R3分别是氢，卤素，低烷基，低烷氧基，氨基甲酰或氰基，R4是氢或低烷基，R5是1H-四唑-5-基，羧基(--COOH)或羧酸酯，R6是氢，卤素，羟基或低烷氧基，或其药学上可接受的盐。

  公开号：

  US05328911A1

文献信息

• CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：NOVARTIS AG

  公开号：US20200164024A1

  公开（公告）日：2020-05-28

  The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , X 1 , X 2 , and X 3 are described herein.

  该披露涉及对PCSK9的抑制剂，用于治疗胆固醇脂质代谢以及其他PCSK9发挥作用的疾病，其化学式为(I)： 或其药用可接受的盐、水合物、溶剂合物、前药、立体异构体、N-氧化物或互变异构体，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、X1、X2和X3如本文所述。
• NOVEL INHIBITORS
  申请人：Heiser Ulrich

  公开号：US20110092501A1

  公开（公告）日：2011-04-21

  The invention relates to novel pyrrolidine derivatives of formula (I): wherein R 1 , R 2 and R 3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

  本发明涉及新颖的吡咯烷衍生物，其具有如下公式(I)：其中R1、R2和R3如本文所述定义，作为谷氨酰胺环化酶（QC，EC 2.3.2.5）的抑制剂。谷氨酰胺环化酶催化N末端谷氨酰胺残基形成焦谷氨酸（5-氧代脯氨酸，pGlu*）的分子内环化，并释放氨，以及催化N末端谷氨酸残基形成焦谷氨酸的分子内环化，并释放水。
• [EN] ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'ARYL-PYRIDINE EN TANT QU'INHIBITEURS D'ALDOSTÉRONE SYNTHASE
  申请人：NOVARTIS AG

  公开号：WO2011061168A1

  公开（公告）日：2011-05-26

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are defined herein. The invention also relates to a method for manufacturing compounds of the invention, and their therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5和n在此处定义。该发明还涉及一种制造该发明化合物的方法，以及它们的治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP
  申请人：KARKI Rajeshri Ganesh

  公开号：US20120122764A1

  公开（公告）日：2012-05-17

  The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.

  本发明提供了一种具有化学式I的化合物； 或其药学上可接受的盐，其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，B，X，m和n在此处被定义。该发明还涉及制造该发明化合物的方法及其治疗用途。本发明进一步提供了该发明化合物的药物组合物，以及具有药理活性剂和该发明化合物的组合。
• Process for the preparation of imidazopyridine derivatives, and
  申请人：Eisai Co., Ltd.

  公开号：US05554757A1

  公开（公告）日：1996-09-10

  The present invention provides an industrially advantageous process for preparing a 2-alkyl-3-(biphenyl-4-yl)methyl-3H-imidazo[4,5-b]pyridine derivative represented by the following formula (II) which is a precursor of an antagonist against an angiotensin II receptor useful as an antihypertensive drug, a biphenyl derivative which is a precursor of the substituent of the pyridine derivative, a process for the preparation thereof, and an intermediate useful for the preparation of the biphenyl derivative: ##STR1## The 2-alkyl-3-(biphenyl-4-yl)methyl-3H-imidazo-[4,5-b]pyridine derivative can be prepared in a high yield according to the present invention from a 2-amino-5-halogeno-3-nitropyridine derivative through amidation, N-alkylation and reductive cyclization. The halogen atom introduced at the 5-position as a protective group against nitration can be eliminated simultaneously in the step which is conducted thereafter. Thus, this process is industrially advantageous. Further, the biphenyl derivative of the present invention is excellent in reactivity and purity of the product, thus being an intermediate suitable for the industrial production.

  本发明提供了一种工业上有利的制备2-烷基-3-(联苯基-4-基)甲基-3H-咪唑并[4,5-b]吡啶衍生物的方法，该衍生物如下式(II)所示，是一种抗肾素II受体拮抗剂的前体，可用作降压药物，联苯衍生物是吡啶衍生物的取代基的前体，提供了其制备方法以及用于制备联苯衍生物的中间体：##STR1## 根据本发明，可以通过酰胺化、N-烷基化和还原环化，以高产率制备2-烷基-3-(联苯基-4-基)甲基-3H-咪唑并[4,5-b]吡啶衍生物。在随后进行的步骤中，引入的5-位卤代基作为对硝化的保护基可以同时被消除。因此，这一方法在工业上具有优势。此外，本发明的联苯衍生物在产物的反应性和纯度方面表现出色，因此是适合工业生产的中间体。